New Delhi: Roche India and Cipla Limited, in a joint statement on Monday, announced the launch of their Antibody Cocktail — ‘Casirivimab and Imdevimab’ for the treatment of mild to moderate COVID-19 in patients in India.
The cocktail drug (Casirivimab and Imdevimab), priced at Rs 59,750 per dose, received emergency use authorisation (EUA) by the Central Drugs Standard Control Organisation (CDSCO) on May 5, for use against the coronavirus disease (Covid-19).
“The first batch is now available in India, while the second one will be made available by mid-June. In total, these can potentially benefit 200,000 patients as each of the 100,000 packs, which will be available in India, offers treatment for two patients,” Roche and Cipla said in a joint statement.
The statement added that the antibody cocktail will be available through leading hospitals, as well as Covid-19 care centres.
India is not the only country that has granted EUA to the cocktail drug. The United States, as well as several member states of the European Union (EU), has granted permission for the product to be used in emergency cases.
The cocktail will be administered for the treatment of mild-to-moderate cases in adults and paediatric patients (12 years or older, and weighing at least 40kg) who are confirmed to be infected with SARS-COV2, and those who face a high risk of developing severe Covid-19 disease.
Comments are closed.